Related references
Note: Only part of the references are listed.2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial
Karen Hambardzumyan et al.
RMD OPEN (2016)
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and MetaAnalysis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
Karen Hambardzumyan et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
Jonas K. Eriksson et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial
Vappu Rantalaiho et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial
P. H. de Jong et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Clinical and Serological Predictors of Remission in Rheumatoid Arthritis Are Dependent on Treatment Regimen
Margaret H. Y. Ma et al.
JOURNAL OF RHEUMATOLOGY (2014)
Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort
Daniel F. McWilliams et al.
BMC MUSCULOSKELETAL DISORDERS (2013)
Therapies for Active Rheumatoid Arthritis after Methotrexate Failure
James R. O'Dell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis
Michael Centola et al.
PLOS ONE (2013)
Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort
Siri Lillegraven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
Hamed Rezaei et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A Randomized Comparative Effectiveness Study of Oral Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis The Treatment of Early Aggressive Rheumatoid Arthritis Trial
Larry W. Moreland et al.
ARTHRITIS AND RHEUMATISM (2012)
Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis
P. Scott Eastman et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2012)
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
Ronald F. van Vollenhoven et al.
LANCET (2012)
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
Jeffrey R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2012)
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
Saedis Saevarsdottir et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis
N. B. Klarenbeek et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study
Sudha Visvanathan et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis
C. Trocme et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
R. F. van Vollenhoven et al.
LANCET (2009)
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients nave to both drugs
Lydia G. Schipper et al.
RHEUMATOLOGY (2009)
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
Wolfgang Hueber et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis
S. Fabre et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis
R Landewé et al.
ARTHRITIS AND RHEUMATISM (2004)
Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission
ETH Molenaar et al.
ARTHRITIS AND RHEUMATISM (2004)
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications - Results of a two-year, randomized, double-blind, placebo-controlled trial
JR O'Dell et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
